PDX Model Cohort
Acute Lymphoblastic Leukemia PDX Models
Advance your B Cell Acute Lymphoblastic Leukemia (B-ALL) therapeutic candidates using a bank of never-passaged and meticulously curated B Cell Acute Lymphoblastic Leukemia PDX models directly established from primary tumors.
Summary
Champions Oncology has developed a comprehensive cohort of patient-derived xenograft (PDX) models for B Cell Acute Lymphoblastic Leukemia (B-ALL) to facilitate translational research and the discovery of novel therapeutic strategies. Our biorepository encompasses a broad spectrum of hematologic malignancies, including ALL, AML, CLL, and MCL, and currently comprises 12* clinically relevant B-Cell Acute Lymphoblastic Leukemia PDX models. These models originate from primary patient samples and are engrafted systemically to faithfully recapitulate patient-specific disease characteristics. Notably, most patient-derived samples were obtained post-treatment with Standard of Care regimens.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading B-ALL cohort showcases primary models, each reflecting key clinical characteristics and pretreatment history.
Rare & well characterized cohort of primary B-Cell Acute Lymphoblastic Leukemia models that recapitulates disease biology
B-ALL model cohort that can be utilized for successful primary ex vivo studies and PDX in vivo studies
Includes models pretreated with advanced cancer therapies post-collection such as CAR-T and those resistant to targeted treatments and the latest immunotherapies.
Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and more).
Offers comprehensive terminal peripheral blood and bone marrow analysis utilizing Champions' high-complexity flow cytometry endpoint, including markers such as hCD10, hCD45, mCD45, hCD3, hCD19, hCD22, hCD20, and Viability Dye.